The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
Abstract Background During the COVID-19 pandemic, some populations, including immunocompromised patients, could not tolerate COVID-19 vaccination or had low responses. Evusheld is a combined neutralizing monoclonal antibody containing tixagevimab and cilgavimab. The World Health Organization (WHO) h...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2024-01-01
|
| Serier: | European Journal of Medical Research |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s40001-023-01549-x |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|